MarginsXMarginsX
Home › Markets › Health Care › CRVO

CervoMed Inc. (CRVO)

CRVO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.67
-1.18% on the day
Market cap
$25.3M
Nano cap
Revenue · 2025
$4.0M
-58.9% on 2024
Net income · 2025
-$27.0M
-673.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/0001437749-26-008259-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRVO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001053691
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$4.0M
Net income-$27.0M
Operating income-$28.3M
Net margin-673.1%
Operating margin-706.2%
Revenue growth-58.9%
Cash$8.2M
Total assets$22.9M
P/E (computed)Net income was not positive
P/S (computed)6.3×

Warning signs

Cash runway
2.7 months
$6.1M cash at September 30, 2026
Share count, 1 year
+63.5%
2025-11-05 to 2026-11-04 · +166.6% over 3 years
Going-concern doubt
Yes
10-Q filed November 6, 2026
Insider net buying, 12 months
$3.5M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, substantial doubt about the Company's ability to continue as a going concern is not alleviated."
10-Q 2026-11-06
Cash and burn$6.1M cash; operating cash flow -$6.6M a quarter.Report 2026-09-30
Shares outstanding15,128,540 (2026-11-04); 9,252,719 a year earlier; 5,674,520 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRSM US LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$5.9M-$5.1M$6.1MNo debt tags$9K10-Q 2026-11-06
Q2 2026
2026-06-30
$0-$6.6M-$6.9M$22.5MNo debt tags$331K10-Q 2026-08-07
Q1 2026
2026-03-31
$0-$8.0M-$8.0M$7.9MNo debt tags$2.1M10-Q 2026-05-15
Q4 2025
2025-12-31
$9K-$8.1M-$6.6M$8.2MNo debt tags$4.0M10-K 2026-03-13
Q3 2025
2025-09-30
$323K-$7.7M-$6.5M$9.4MNo debt tags$6.2M10-Q 2026-11-06
Q2 2025
2025-06-30
$1.8M-$6.3M-$6.5M$8.3MNo debt tags$7.8M10-Q 2026-08-07
Q1 2025
2025-03-31
$1.9M-$4.9M-$3.9M$10.5MNo debt tags$9.3M10-Q 2026-05-15
Q4 2024
2024-12-31
$2.2M-$6.7M-$8.1M$9.0MNo debt tags$9.7M10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B3
424B32026-07-10
Latest annual report
FORM 10-K
10-K2026-03-13
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-06
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxy
FORM DEF 14A
DEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+19.0%
1 month-25.6%
3 months-42.3%
Year to date-78.6%
1 year-76.7%
From 52-week high-83.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
IMMPImmutep Limited$3.40-2.30%$25.1M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
BYSIBeyondSpring Inc.$0.5788-3.73%$23.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier